Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

  • Technology appraisal guidance
  • TA394
  • Published: 

History

Expected publication

Final appraisal determination

Draft guidance: 2

Draft guidance: 1

Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab: final scope

Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab: final matrix

Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab: NICE response to comments on the draft scope and provisional matrix

Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab: provisional matrix (pre-referral) July 2014

Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab: draft scope for consultation (pre-referral) July 2014